Gevorg Yaghjyan/LinkedIn
Apr 2, 2026, 15:52
Gevorg Yaghjyan: How Yale is Redefining Bladder Cancer Treatment Through Strategy Focused Trials
Gevorg Yaghjyan, Former Project Leader at Parexel, shared a post on LinkedIn:
“Clinical trials are evolving from testing drugs to testing strategies.
A new study from Yale School of Medicine in metastatic bladder cancer highlights this shift:
- Systemic therapy (ADC plus immunotherapy)
- Response-based patient selection
- Consolidative surgery in responders
This is not a traditional trial.
It’s a multimodal, adaptive treatment pathway.
From a clinical development perspective, key takeaways:
- Dynamic, response – driven enrollment
- Integration of medical plus surgical oncology
- Increasing operational complexity at site level
- Movement toward strategy – based endpoints
This is where oncology trials are heading:
From molecule-focused – to patient pathway – focused design”
Stay updated with Hemostasis Today.
-
Apr 2, 2026, 15:10Webinar on the Role of Omega-3 Fatty Acids in Cardiovascular Health – EAS
-
Apr 2, 2026, 15:06Leonardo Roever: Atherofrailty Score Offers a A Novel Machine Learning Approach to Stroke Risk Stratification
-
Apr 2, 2026, 14:55André da Silva: Stroke Is Not an Explosion – It’s Often a Silent Loss of Blood Flow
-
Apr 2, 2026, 14:39Maria Τektonidou: STAT1 as a Potential Therapeutic Target in Thrombotic Antiphospholipid Syndrome
-
Apr 2, 2026, 14:18Deise Catamo Vaz: WSO Future Stroke Leaders Project Offers A Closing for Large Information Gap in PSCI
-
Apr 2, 2026, 14:18Abdul Mannan: Free Warfarin and Thrombosis Management Tool for Clinicians
-
Apr 2, 2026, 14:06Mike Sharma Named 2026 Hnatyshyn Lecturer for His Profound Impact on Stroke Care – Heart and Stroke
-
Apr 2, 2026, 13:53Ahvie Herskowitz: Therapeutic Plasma Exchange as a Precision Cancer Weapon
-
Apr 2, 2026, 13:51Clare Woodford: New NHS Access to Semaglutide Offers Hope to Prevent Another Stroke or Heart Attack